Valuation: MiNK Therapeutics, Inc.

Market Cap 59.76M 52.05M 49.26M 44.76M 83.61M 5.72B 84.02M 587M 227M 2.91B 224M 219M 9.31B P/E 2026 *
-6.07x
P/E 2027 * -4.43x
Enterprise Value 59.76M 52.05M 49.26M 44.76M 83.61M 5.72B 84.02M 587M 227M 2.91B 224M 219M 9.31B EV / Sales 2026 *
17.6x
EV / Sales 2027 * 29.9x
Free-Float
40.63%
Yield 2026 *
-
Yield 2027 * -
1 day+1.04%
1 week-3.46%
Current month+5.59%
1 month+4.37%
3 months-4.10%
6 months+22.36%
Current year+5.02%
1 week 11.31
Extreme 11.3064
12.4
1 month 10.82
Extreme 10.82
12.69
Current year 8.48
Extreme 8.4801
16.93
1 year 8.48
Extreme 8.4801
16.98
3 years 4.56
Extreme 4.5601
76
5 years 4.56
Extreme 4.5601
221.55
10 years 4.56
Extreme 4.5601
221.55
Manager TitleAgeSince
Chief Executive Officer 52 2021-01-31
Director of Finance/CFO 37 2026-03-12
Comptroller/Controller/Auditor 37 2026-03-12
Director TitleAgeSince
Director/Board Member 52 2021-01-31
Chairman 73 2017-06-30
Director/Board Member 62 2021-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Free

Director

1,622 0.0318%
9/1/26 Free

Director

1,279 0.0251%
9/1/26 Free

Director

1,633 0.0320%
Change 5-day change 1-year change 3-year change Capi.($)
+1.04%-3.46%-17.77%-9.22% 59.14M
+1.23%+1.87%-0.15%+9.57% 45.91B
+0.23%+4.72%+44.32%+27.27% 44.25B
+0.52%-3.15%+349.53%+520.09% 41.99B
+1.55%+3.41%+6.40%+76.45% 39.58B
+1.75%-0.28%+12.42%+41.11% 31.08B
-0.20%+5.49%+23.57%+119.72% 17.21B
-3.49%-8.49% - - 16.27B
+2.92%+8.40%+22.46%+38.87% 14.96B
-2.45%+2.41%-3.16%-35.16% 13.42B
Average +0.31%+0.43%+48.63%+87.63% 26.47B
Weighted average by Cap. +0.59%+0.33%+72.33%+120.58%

Financials

2026 *2027 *
Net sales 3.4M 2.96M 2.8M 2.55M 4.76M 326M 4.78M 33.38M 12.91M 165M 12.77M 12.49M 530M 2M 1.74M 1.65M 1.5M 2.8M 192M 2.81M 19.64M 7.59M 97.34M 7.51M 7.35M 312M
Net income -9.6M -8.36M -7.91M -7.19M -13.43M -919M -13.5M -94.26M -36.45M -467M -36.06M -35.26M -1.5B -15.1M -13.15M -12.44M -11.31M -21.12M -1.45B -21.23M -148M -57.32M -735M -56.71M -55.45M -2.35B
Net Debt - -
Logo MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Employees
15
Date Price Change Volume
26-09-17 US$11.71 +1.04% 3,606
26-09-16 US$11.59 +1.58% 4,800
26-09-15 US$11.41 -4.68% 15,768
26-09-14 US$11.97 -0.25% 55,929
26-09-11 US$12.00 -1.07% 42,354
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.71USD
Average target price
39.00USD
Spread / Average Target
+233.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INKT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!